⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Semaglutide (weekly injection)

سماگلوتاید (تزریقی هفتگی)

⚠ Unverified

🍽️ Alimentary Tract And MetabolismGLP-1 receptor agonist

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution ⚥ Females & males of reproductive potential:Use with caution 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA209637 ATC A10BJ06

Market / country: 🇺🇸 USA

Ozempic (US)

🧮 Dose calculator

Disease / regimen

Type 2 diabetes mellitus · Regimen source: FDA Ozempic · 2.2 FDA Ozempic · 2.1

⛔ Once WEEKLY subcutaneous (not daily). 0.25 mg for 4 weeks (tolerability only), then 0.5 mg. If needed after at least 4 weeks go to 1 mg, then 2 mg; max 2 mg weekly. FDA Ozempic · 2.2 FDA Ozempic · 2.1

🛡️ Safety & information

Contraindications

⛔ Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity. FDA Ozempic · 4 FDA Wegovy · 4

Warnings

• Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history. FDA Ozempic · Boxed Warning

Formulations

Pen 0.25/0.5 mg, 1 mg or 2 mg per dose (0.68, 1.34 or 2.68 mg/mL) — injection 🇺🇸 USA FDA Ozempic · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ozempic · 8.1
“Risk Summary There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ozempic · 8.2
“Risk Summary There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ozempic · 8.4
“Safety and efficacy of OZEMPIC have not been established in pediatric patients.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ozempic · 8.5
“In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC-treated patients were 65 years of age and over and 102 OZEMPIC-treated patients (3.2%) patients were 75 years of age and over.”
⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Ozempic · 8.3
“Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide [see Use in Specific Populations ( 8.1 )] .”

🔗 Reference links

FDA (approval record)NDA209637
DailyMed (FDA label)FDA Ozempic
MedlinePlus (NIH)Semaglutide Semaglutide Injection
WHO ATC/DDDA10BJ06
Darooyab (Iran)Semaglutide

🇮🇷 Registered in Iran Darooyab · G-5532/Semaglutide

Dosage forms with Iranian generic codes, per Darooyab.

53482 · SEMAGLUTIDE INJECTION, SOLUTION PARENTERAL 4 mg/3 mL · محلول تزریقی سماگلوتاید ۴ میلی‌گرم / ۳ میلی‌لیتر
53491 · SEMAGLUTIDE INJECTION, SOLUTION PARENTERAL 8 mg/3 mL · محلول تزریقی سماگلوتاید ۸ میلی‌گرم / ۳ میلی‌لیتر

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Ozempic · 3 FDA Ozempic · 2.2 FDA Ozempic · 2.1 FDA Wegovy · 2.2, Table 1 FDA Wegovy · 2.2 FDA Ozempic · 4 FDA Wegovy · 4 FDA Ozempic · Boxed Warning FDA Ozempic · 8.1 FDA Ozempic · 8.2 FDA Ozempic · 8.4 FDA Ozempic · 8.5 FDA Ozempic · 8.3 FDA Ozempic · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-5532/Semaglutide
Clinical review⚠ Unverified